{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:26:48Z","timestamp":1778084808655,"version":"3.51.4"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2022.13102.BD"],"award-info":[{"award-number":["2022.13102.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006742","name":"Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio","doi-asserted-by":"publisher","award":["ChImuRet_GI2-CESPU-2023"],"award-info":[{"award-number":["ChImuRet_GI2-CESPU-2023"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Rectal cancer accounts for over 35% of the worldwide colorectal cancer burden representing a distinctive subset of cancers from those arising in the colon. Colorectal cancers exhibit a continuum of traits that differ with their location in the large intestine. Due to anatomical and molecular differences, rectal cancer is treated differently from colon cancer, with neoadjuvant chemoradiotherapy playing a pivotal role in the control of the locally advanced disease. However, radioresistance remains a major obstacle often correlated with poor prognosis. Multifunctional nanomedicines offer a promising approach to improve radiotherapy response rates, as well as to increase the intratumoral concentration of chemotherapeutic agents, such as 5-Fluorouracil. Here, we revise the main molecular differences between rectal and colon tumors, exploring the complex orchestration beyond rectal cancer radioresistance and the most promising nanomedicines reported in the literature to improve neoadjuvant therapy response rates.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1186\/s12943-025-02232-x","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T12:17:56Z","timestamp":1738239476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Radioresistance in rectal cancer: can nanoparticles turn the tide?"],"prefix":"10.1186","volume":"24","author":[{"given":"Diogo","family":"Coelho","sequence":"first","affiliation":[]},{"given":"Diogo","family":"Est\u00eav\u00e3o","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"issue":"1","key":"2232_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"5","key":"2232_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"3","key":"2232_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2232_CR4","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338\u201344.","journal-title":"Gut"},{"issue":"1","key":"2232_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2232_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jamasurg.2014.1756","volume":"150","author":"CE Bailey","year":"2015","unstructured":"Bailey CE, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975\u20132010. JAMA Surg. 2015;150(1):17\u201322.","journal-title":"JAMA Surg"},{"issue":"1","key":"2232_CR7","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1186\/s12885-018-4786-7","volume":"18","author":"A White","year":"2018","unstructured":"White A, Ironmonger L, Steele RJC, Ormiston-Smith N, Crawford C, Seims A. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer. 2018;18(1):906.","journal-title":"BMC Cancer"},{"issue":"1","key":"2232_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13293-024-00623-1","volume":"15","author":"Y Rodriguez-Santiago","year":"2024","unstructured":"Rodriguez-Santiago Y, Garay-Canales CA, Nava-Castro KE, Morales-Montor J. Sexual dimorphism in colorectal cancer: molecular mechanisms and treatment strategies. Biol Sex Differ. 2024;15(1):48.","journal-title":"Biol Sex Differ"},{"issue":"6","key":"2232_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s13402-023-00828-3","volume":"46","author":"D Estevao","year":"2023","unstructured":"Estevao D, da Cruz-Ribeiro M, Cardoso AP, Costa AM, Oliveira MJ, Duarte TL, et al. Iron metabolism in colorectal cancer: a balancing act. Cell Oncol (Dordr). 2023;46(6):1545\u201358.","journal-title":"Cell Oncol (Dordr)"},{"issue":"suppl_4","key":"2232_CR10","doi-asserted-by":"publisher","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","volume":"28","author":"R Glynne-Jones","year":"2017","unstructured":"Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22\u201340.","journal-title":"Ann Oncol."},{"issue":"18","key":"2232_CR11","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-19-0908","volume":"25","author":"SC Kamran","year":"2019","unstructured":"Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clin Cancer Res. 2019;25(18):5561\u201371.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2232_CR12","doi-asserted-by":"publisher","first-page":"e2307858","DOI":"10.1002\/advs.202307858","volume":"11","author":"L Wang","year":"2024","unstructured":"Wang L, Zhou H, Chen Q, Lin Z, Jiang C, Chen X, et al. STING Agonist-Loaded Nanoparticles Promotes Positive Regulation of Type I Interferon-Dependent Radioimmunotherapy in Rectal Cancer. Adv Sci (Weinh). 2024;11(7):e2307858.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2232_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/0008-5472.CAN-15-2951","volume":"77","author":"X Tian","year":"2017","unstructured":"Tian X, Nguyen M, Foote HP, Caster JM, Roche KC, Peters CG, et al. CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1alpha. Cancer Res. 2017;77(1):112\u201322.","journal-title":"Cancer Res"},{"key":"2232_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","volume":"157","author":"J Fang","year":"2020","unstructured":"Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv Drug Deliv Rev. 2020;157:142\u201360.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2232_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101\u201324.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2232_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3892\/ijo_00000720","volume":"37","author":"P Minoo","year":"2010","unstructured":"Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol. 2010;37(3):707\u201318.","journal-title":"Int J Oncol"},{"key":"2232_CR17","doi-asserted-by":"crossref","unstructured":"Carmichael JC, Mills S. Anatomy and Embryology of the Colon, Rectum, and Anus. The ASCRS Textbook of Colon and Rectal Surgery.\u00a0Cham, Switzerland: Springer International Publishing; 2016. p. 3\u201326.","DOI":"10.1007\/978-3-319-25970-3_1"},{"key":"2232_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejca.2018.08.020","volume":"103","author":"ME Salem","year":"2018","unstructured":"Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, et al. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. Eur J Cancer. 2018;103:205\u201313.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2232_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s11605-008-0757-7","volume":"13","author":"KK Tan","year":"2009","unstructured":"Tan KK, Lopes Gde L, Jr., Sim R. How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years. J Gastrointest Surg. 2009;13(4):642\u20138.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"2232_CR20","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1038\/s41598-024-55139-w","volume":"14","author":"I Ciepiela","year":"2024","unstructured":"Ciepiela I, Szczepaniak M, Ciepiela P, Hincza-Nowak K, Kopczynski J, Macek P, et al. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients. Sci Rep. 2024;14(1):4619.","journal-title":"Sci Rep"},{"issue":"3","key":"2232_CR21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/annonc\/mdt591","volume":"25","author":"N Hugen","year":"2014","unstructured":"Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25(3):651\u20137.","journal-title":"Ann Oncol"},{"key":"2232_CR22","doi-asserted-by":"publisher","first-page":"29765","DOI":"10.1038\/srep29765","volume":"6","author":"M Riihimaki","year":"2016","unstructured":"Riihimaki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765.","journal-title":"Sci Rep"},{"issue":"9","key":"2232_CR23","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.3390\/ijms19092577","volume":"19","author":"S Paschke","year":"2018","unstructured":"Paschke S, Jafarov S, Staib L, Kreuser ED, Maulbecker-Armstrong C, Roitman M, et al. Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer. Int J Mol Sci. 2018;19(9):2577.","journal-title":"Int J Mol Sci."},{"issue":"3","key":"2232_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1631\/jzus.B0820273","volume":"10","author":"FY Li","year":"2009","unstructured":"Li FY, Lai MD. Colorectal cancer, one entity or three. J Zhejiang Univ Sci B. 2009;10(3):219\u201329.","journal-title":"J Zhejiang Univ Sci B"},{"issue":"10","key":"2232_CR25","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","volume":"25","author":"E Missiaglia","year":"2014","unstructured":"Missiaglia E, Jacobs B, D\u2019Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995\u20132001.","journal-title":"Ann Oncol"},{"issue":"3","key":"2232_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejso.2014.11.001","volume":"41","author":"GH Lee","year":"2015","unstructured":"Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review. Eur J Surg Oncol. 2015;41(3):300\u20138.","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"2232_CR27","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41591-022-01930-z","volume":"28","author":"WK Chatila","year":"2022","unstructured":"Chatila WK, Kim JK, Walch H, Marco MR, Chen CT, Wu F, et al. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nat Med. 2022;28(8):1646\u201355.","journal-title":"Nat Med"},{"issue":"5","key":"2232_CR28","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1053\/j.gastro.2020.07.041","volume":"159","author":"S Mondaca","year":"2020","unstructured":"Mondaca S, Walch H, Nandakumar S, Chatila WK, Schultz N, Yaeger R. Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer. Gastroenterology. 2020;159(5):1975\u20138 e4.","journal-title":"Gastroenterology."},{"issue":"4","key":"2232_CR29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdz052","volume":"30","author":"E Fontana","year":"2019","unstructured":"Fontana E, Eason K, Cervantes A, Salazar R, Sadanandam A. Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Ann Oncol. 2019;30(4):520\u20137.","journal-title":"Ann Oncol"},{"issue":"3","key":"2232_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14(3):275\u201391.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2232_CR31","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","volume":"61","author":"ER Fearon","year":"1990","unstructured":"Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759\u201367.","journal-title":"Cell"},{"issue":"2","key":"2232_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1053\/j.gastro.2019.08.059","volume":"158","author":"LH Nguyen","year":"2020","unstructured":"Nguyen LH, Goel A, Chung DC. Pathways of Colorectal Carcinogenesis. Gastroenterology. 2020;158(2):291\u2013302.","journal-title":"Gastroenterology"},{"issue":"12","key":"2232_CR33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","volume":"16","author":"N Keum","year":"2019","unstructured":"Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713\u201332.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"2232_CR34","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1053\/j.gastro.2009.12.065","volume":"138","author":"MS Pino","year":"2010","unstructured":"Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138(6):2059\u201372.","journal-title":"Gastroenterology"},{"issue":"23","key":"2232_CR35","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-11-1570","volume":"17","author":"R Sanz-Pamplona","year":"2011","unstructured":"Sanz-Pamplona R, Cordero D, Berenguer A, Lejbkowicz F, Rennert H, Salazar R, et al. Gene expression differences between colon and rectum tumors. Clin Cancer Res. 2011;17(23):7303\u201312.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2232_CR36","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/bjc.2013.430","volume":"109","author":"JM Bae","year":"2013","unstructured":"Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer. 2013;109(4):1004\u201312.","journal-title":"Br J Cancer"},{"key":"2232_CR37","first-page":"PO.17.00073","volume":"2017","author":"R Bonneville","year":"2017","unstructured":"Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2017;2017:PO.17.00073.","journal-title":"JCO Precis Oncol."},{"issue":"11","key":"2232_CR38","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/nm.4191","volume":"22","author":"RJ Hause","year":"2016","unstructured":"Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342\u201350.","journal-title":"Nat Med"},{"issue":"6","key":"2232_CR39","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/gutjnl-2011-300865","volume":"61","author":"M Yamauchi","year":"2012","unstructured":"Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61(6):847\u201354.","journal-title":"Gut"},{"issue":"49","key":"2232_CR40","doi-asserted-by":"publisher","first-page":"86356","DOI":"10.18632\/oncotarget.21169","volume":"8","author":"ME Salem","year":"2017","unstructured":"Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8(49):86356\u201368.","journal-title":"Oncotarget"},{"issue":"1","key":"2232_CR41","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1038\/s41467-020-17386-z","volume":"11","author":"SH Zaidi","year":"2020","unstructured":"Zaidi SH, Harrison TA, Phipps AI, Steinfelder R, Trinh QM, Qu C, et al. Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nat Commun. 2020;11(1):3644.","journal-title":"Nat Commun"},{"issue":"7407","key":"2232_CR42","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330\u20137.","journal-title":"Nature."},{"issue":"1","key":"2232_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8(1):92.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"2232_CR44","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/cncr.28599","volume":"120","author":"AL Russo","year":"2014","unstructured":"Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014;120(10):1482\u201390.","journal-title":"Cancer"},{"issue":"2","key":"2232_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/path.918","volume":"195","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, et al. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol. 2001;195(2):171\u20138.","journal-title":"J Pathol"},{"issue":"1","key":"2232_CR46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12943-022-01616-7","volume":"21","author":"H Zhao","year":"2022","unstructured":"Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer. 2022;21(1):144.","journal-title":"Mol Cancer"},{"issue":"12 Pt 1","key":"2232_CR47","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1158\/1078-0432.CCR-04-0031","volume":"10","author":"M Frattini","year":"2004","unstructured":"Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res. 2004;10(12 Pt 1):4015\u201321.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2232_CR48","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/annonc\/mdl035","volume":"17","author":"B Iacopetta","year":"2006","unstructured":"Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol. 2006;17(5):842\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"2232_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","volume":"33","author":"R Yaeger","year":"2018","unstructured":"Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, et al. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell. 2018;33(1):125\u201336 e3.","journal-title":"Cancer Cell."},{"issue":"4","key":"2232_CR50","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1053\/j.gastro.2019.06.041","volume":"157","author":"SD Crockett","year":"2019","unstructured":"Crockett SD, Nagtegaal ID. Terminology, Molecular Features, Epidemiology, and Management of Serrated Colorectal Neoplasia. Gastroenterology. 2019;157(4):949\u201366 e4.","journal-title":"Gastroenterology."},{"issue":"9","key":"2232_CR51","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/ajg.2012.161","volume":"107","author":"DK Rex","year":"2012","unstructured":"Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107(9):1315\u201329 quiz 4, 30.","journal-title":"Am J Gastroenterol."},{"issue":"20","key":"2232_CR52","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1158\/1078-0432.CCR-09-1438","volume":"15","author":"S Ogino","year":"2009","unstructured":"Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009;15(20):6412\u201320.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2232_CR53","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.3390\/cancers13215545","volume":"13","author":"A Mezheyeuski","year":"2021","unstructured":"Mezheyeuski A, Micke P, Martin-Bernabe A, Backman M, Hrynchyk I, Hammarstrom K, et al. The Immune Landscape of Colorectal Cancer. Cancers (Basel). 2021;13(21):5545.","journal-title":"Cancers (Basel)."},{"issue":"8","key":"2232_CR54","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/cancers12082227","volume":"12","author":"JM Sendoya","year":"2020","unstructured":"Sendoya JM, Iseas S, Coraglio M, Golubicki M, Robbio J, Salanova R, et al. Pre-Existing Tumoral B Cell Infiltration and Impaired Genome Maintenance Correlate with Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. Cancers (Basel). 2020;12(8):2227.","journal-title":"Cancers (Basel)."},{"issue":"11","key":"2232_CR55","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350\u20136.","journal-title":"Nat Med"},{"issue":"7","key":"2232_CR56","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10350-004-6317-7","volume":"45","author":"A Wibe","year":"2002","unstructured":"Wibe A, Moller B, Norstein J, Carlsen E, Wiig JN, Heald RJ, et al. A national strategic change in treatment policy for rectal cancer\u2013implementation of total mesorectal excision as routine treatment in Norway. A national audit Dis Colon Rectum. 2002;45(7):857\u201366.","journal-title":"A national audit Dis Colon Rectum"},{"issue":"9","key":"2232_CR57","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1463-1318.2006.01139.x","volume":"8","author":"R Glynne-Jones","year":"2006","unstructured":"Glynne-Jones R, Mawdsley S, Novell JR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis. 2006;8(9):800\u20137.","journal-title":"Colorectal Dis"},{"issue":"7","key":"2232_CR58","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41575-020-0275-y","volume":"17","author":"DS Keller","year":"2020","unstructured":"Keller DS, Berho M, Perez RO, Wexner SD, Chand M. The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol. 2020;17(7):414\u201329.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"2232_CR59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1158\/2159-8290.CD-11-0315","volume":"2","author":"TS Hong","year":"2012","unstructured":"Hong TS, Clark JW, Haigis KM. Cancers of the colon and rectum: identical or fraternal twins? Cancer Discov. 2012;2(2):117\u201321.","journal-title":"Cancer Discov"},{"issue":"5","key":"2232_CR60","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/SLA.0b013e3181dae4ed","volume":"251","author":"BC Paun","year":"2010","unstructured":"Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010;251(5):807\u201318.","journal-title":"Ann Surg"},{"issue":"14","key":"2232_CR61","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJM199704033361402","volume":"336","author":"B Cedermark","year":"1997","unstructured":"Swedish Rectal Cancer T, Cedermark B, Dahlberg M, Glimelius B, Pahlman L, Rutqvist LE, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980\u20137.","journal-title":"N Engl J Med."},{"issue":"9","key":"2232_CR62","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638\u201346.","journal-title":"N Engl J Med"},{"issue":"24","key":"2232_CR63","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1200\/JCO.2005.08.144","volume":"23","author":"J Folkesson","year":"2005","unstructured":"Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644\u201350.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2232_CR64","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W van Gijn","year":"2011","unstructured":"van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575\u201382.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2232_CR65","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114\u201323.","journal-title":"N Engl J Med"},{"issue":"17","key":"2232_CR66","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731\u201340.","journal-title":"N Engl J Med"},{"issue":"19","key":"2232_CR67","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andre","year":"2009","unstructured":"Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109\u201316.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2232_CR68","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","volume":"16","author":"C Rodel","year":"2015","unstructured":"Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979\u201389.","journal-title":"Lancet Oncol"},{"issue":"20","key":"2232_CR69","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","volume":"29","author":"C Aschele","year":"2011","unstructured":"Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773\u201380.","journal-title":"J Clin Oncol"},{"issue":"36","key":"2232_CR70","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1200\/JCO.2012.42.8771","volume":"30","author":"JP Gerard","year":"2012","unstructured":"Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12\/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558\u201365.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2232_CR71","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.2013.53.7753","volume":"32","author":"MJ O'Connell","year":"2014","unstructured":"O\u2019Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32(18):1927\u201334.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2232_CR72","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/jamaoncol.2020.2394","volume":"6","author":"M Diefenhardt","year":"2020","unstructured":"Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rodel C, et al. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO\/ARO\/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(9):1416\u201321.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2232_CR73","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29\u201342.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2232_CR74","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, Rio E, Francois E, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702\u201315.","journal-title":"Lancet Oncol"},{"issue":"34","key":"2232_CR75","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.19.00308","volume":"37","author":"E Fokas","year":"2019","unstructured":"Fokas E, Allgauer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO\/ARO\/AIO-12. J Clin Oncol. 2019;37(34):3212\u201322.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2232_CR76","doi-asserted-by":"publisher","first-page":"e215445","DOI":"10.1001\/jamaoncol.2021.5445","volume":"8","author":"E Fokas","year":"2022","unstructured":"Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO\/ARO\/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2022;8(1):e215445.","journal-title":"JAMA Oncol"},{"issue":"10","key":"2232_CR77","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","volume":"20","author":"AB Benson","year":"2022","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(10):1139\u201367.","journal-title":"J Natl Compr Canc Netw."},{"issue":"2","key":"2232_CR78","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1470-2045(15)00467-2","volume":"17","author":"AG Renehan","year":"2016","unstructured":"Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17(2):174\u201383.","journal-title":"Lancet Oncol"},{"issue":"23","key":"2232_CR79","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022;40(23):2546\u201356.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2232_CR80","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.23.01208","volume":"42","author":"FS Verheij","year":"2024","unstructured":"Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol. 2024;42(5):500\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2232_CR81","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa2303269","volume":"389","author":"D Schrag","year":"2023","unstructured":"Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023;389(4):322\u201334.","journal-title":"N Engl J Med"},{"issue":"10","key":"2232_CR82","doi-asserted-by":"publisher","first-page":"e2236666","DOI":"10.1001\/jamanetworkopen.2022.36666","volume":"5","author":"N Reboux","year":"2022","unstructured":"Reboux N, Jooste V, Goungounga J, Robaszkiewicz M, Nousbaum JB, Bouvier AM. Incidence and Survival in Synchronous and Metachronous Liver Metastases From Colorectal Cancer. JAMA Netw Open. 2022;5(10):e2236666.","journal-title":"JAMA Netw Open"},{"issue":"10125","key":"2232_CR83","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375.","journal-title":"Lancet"},{"issue":"6","key":"2232_CR84","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361\u201375.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"2232_CR85","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","volume":"7","author":"OE Rahma","year":"2021","unstructured":"Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, et al. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(8):1225\u201330.","journal-title":"JAMA Oncol"},{"issue":"25","key":"2232_CR86","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363\u201376.","journal-title":"N Engl J Med"},{"issue":"2","key":"2232_CR87","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(16)30648-9","volume":"18","author":"JG Scott","year":"2017","unstructured":"Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2017;18(2):202\u201311.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2232_CR88","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nrc2587","volume":"9","author":"GC Barnett","year":"2009","unstructured":"Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009;9(2):134\u201342.","journal-title":"Nat Rev Cancer"},{"key":"2232_CR89","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fmolb.2014.00024","volume":"1","author":"R Baskar","year":"2014","unstructured":"Baskar R, Dai J, Wenlong N, Yeo R, Yeoh KW. Biological response of cancer cells to radiation treatment. Front Mol Biosci. 2014;1:24.","journal-title":"Front Mol Biosci"},{"issue":"9","key":"2232_CR90","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","volume":"12","author":"D Schaue","year":"2015","unstructured":"Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015;12(9):527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2232_CR91","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/annonc\/mdw062","volume":"27","author":"K Bujko","year":"2016","unstructured":"Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Krynski J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834\u201342.","journal-title":"Ann Oncol"},{"issue":"8","key":"2232_CR92","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/annonc\/mdz186","volume":"30","author":"B Cisel","year":"2019","unstructured":"Cisel B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298\u2013303.","journal-title":"Ann Oncol"},{"issue":"2","key":"2232_CR93","doi-asserted-by":"publisher","first-page":"113735","DOI":"10.1016\/j.celrep.2024.113735","volume":"43","author":"D Andel","year":"2024","unstructured":"Andel D, Viergever BJ, Peters NA, Elisabeth Raats DA, Schenning-van Schelven SJ, Willem Intven MP, et al. Pre-existing subclones determine radioresistance in rectal cancer organoids. Cell Rep. 2024;43(2):113735.","journal-title":"Cell Rep"},{"issue":"1","key":"2232_CR94","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, Song Y, Wang R, Wang T. Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023;22(1):96.","journal-title":"Mol Cancer"},{"issue":"8","key":"2232_CR95","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrm.2017.48","volume":"18","author":"HHY Chang","year":"2017","unstructured":"Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18(8):495\u2013506.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2232_CR96","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41419-022-05402-7","volume":"13","author":"Y Yu","year":"2022","unstructured":"Yu Y, Liu T, Yu G, Wang H, Du Z, Chen Y, et al. PRDM15 interacts with DNA-PK-Ku complex to promote radioresistance in rectal cancer by facilitating DNA damage repair. Cell Death Dis. 2022;13(11):978.","journal-title":"Cell Death Dis"},{"issue":"6","key":"2232_CR97","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00109-019-01760-6","volume":"97","author":"AR Baptistella","year":"2019","unstructured":"Baptistella AR, Landemberger MC, Dias MVS, Giudice FS, Rodrigues BR, da Silva P, et al. Rab5C enhances resistance to ionizing radiation in rectal cancer. J Mol Med (Berl). 2019;97(6):855\u201369.","journal-title":"J Mol Med (Berl)"},{"key":"2232_CR98","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neo.2022.01.004","volume":"25","author":"M Smithson","year":"2022","unstructured":"Smithson M, Irwin RK, Williams G, McLeod MC, Choi EK, Ganguly A, et al. Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer. Neoplasia. 2022;25:53\u201361.","journal-title":"Neoplasia"},{"issue":"3","key":"2232_CR99","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1158\/0008-5472.CAN-17-0524","volume":"78","author":"J Tommelein","year":"2018","unstructured":"Tommelein J, De Vlieghere E, Verset L, Melsens E, Leenders J, Descamps B, et al. Radiotherapy-Activated Cancer-Associated Fibroblasts Promote Tumor Progression through Paracrine IGF1R Activation. Cancer Res. 2018;78(3):659\u201370.","journal-title":"Cancer Res"},{"issue":"2","key":"2232_CR100","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2022.01.004","volume":"40","author":"AM Nicolas","year":"2022","unstructured":"Nicolas AM, Pesic M, Engel E, Ziegler PK, Diefenhardt M, Kennel KB, et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell. 2022;40(2):168\u201384 e13.","journal-title":"Cancer Cell."},{"key":"2232_CR101","first-page":"99","volume":"34","author":"M Fleischmann","year":"2022","unstructured":"Fleischmann M, Diefenhardt M, Nicolas AM, Rodel F, Ghadimi M, Hofheinz RD, et al. ACO\/ARO\/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. Clin Transl Radiat Oncol. 2022;34:99\u2013106.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"2232_CR102","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12943-023-01877-w","volume":"22","author":"Z Zeng","year":"2023","unstructured":"Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. Mol Cancer. 2023;22(1):172.","journal-title":"Mol Cancer"},{"issue":"10","key":"2232_CR103","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124\u201334.","journal-title":"Nat Med"},{"key":"2232_CR104","doi-asserted-by":"publisher","first-page":"101304","DOI":"10.1016\/j.tranon.2021.101304","volume":"18","author":"SY Xiao","year":"2022","unstructured":"Xiao SY, Yan ZG, Zhu XD, Qiu J, Lu YC, Zeng FR. LncRNA DLGAP1-AS2 promotes the radioresistance of rectal cancer stem cells by upregulating CD151 expression via E2F1. Transl Oncol. 2022;18:101304.","journal-title":"Transl Oncol"},{"issue":"9","key":"2232_CR105","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.neo.2019.07.005","volume":"21","author":"HT Ha Thi","year":"2019","unstructured":"Ha Thi HT, Kim HY, Kim YM, Hong S. MicroRNA-130a modulates a radiosensitivity of rectal cancer by targeting SOX4. Neoplasia. 2019;21(9):882\u201392.","journal-title":"Neoplasia"},{"issue":"15_suppl","key":"2232_CR106","doi-asserted-by":"publisher","first-page":"e15081","DOI":"10.1200\/JCO.2017.35.15_suppl.e15081","volume":"35","author":"SHS Lim","year":"2017","unstructured":"Lim SHS, Ip E, Chua W, Ng W, Henderson C, Shin JS, et al. Serum microRNA expression during neoadjuvant chemoradiation for rectal cancer. J Clin Oncol. 2017;35(15_suppl):e15081\u2013e.","journal-title":"J Clin Oncol."},{"issue":"4","key":"2232_CR107","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","volume":"59","author":"TM Pawlik","year":"2004","unstructured":"Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"2232_CR108","doi-asserted-by":"publisher","first-page":"e45388","DOI":"10.1371\/journal.pone.0045388","volume":"7","author":"MB Chen","year":"2012","unstructured":"Chen MB, Wu XY, Yu R, Li C, Wang LQ, Shen W, et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS ONE. 2012;7(9):e45388.","journal-title":"PLoS ONE"},{"key":"2232_CR109","doi-asserted-by":"publisher","first-page":"801880","DOI":"10.3389\/fonc.2021.801880","volume":"11","author":"S Iseas","year":"2021","unstructured":"Iseas S, Sendoya JM, Robbio J, Coraglio M, Kujaruk M, Mikolaitis V, et al. Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer. Front Oncol. 2021;11:801880.","journal-title":"Front Oncol"},{"issue":"1","key":"2232_CR110","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/BF02236898","volume":"41","author":"CG Fu","year":"1998","unstructured":"Fu CG, Tominaga O, Nagawa H, Nita ME, Masaki T, Ishimaru G, et al. Role of p53 and p21\/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum. 1998;41(1):68\u201374.","journal-title":"Dis Colon Rectum"},{"issue":"25","key":"2232_CR111","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1038\/s41388-022-02352-4","volume":"41","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zhou S, Wan K, Yu L, Zhao C, Deng H, et al. RIOK1 mediates p53 degradation and radioresistance in colorectal cancer through phosphorylation of G3BP2. Oncogene. 2022;41(25):3433\u201344.","journal-title":"Oncogene"},{"issue":"10","key":"2232_CR112","doi-asserted-by":"publisher","first-page":"e1802228","DOI":"10.1002\/adma.201802228","volume":"31","author":"Q Chen","year":"2019","unstructured":"Chen Q, Chen J, Yang Z, Xu J, Xu L, Liang C, et al. Nanoparticle-Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy. Adv Mater. 2019;31(10):e1802228.","journal-title":"Adv Mater"},{"issue":"1","key":"2232_CR113","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41467-023-37328-9","volume":"14","author":"P Zhang","year":"2023","unstructured":"Zhang P, Rashidi A, Zhao J, Silvers C, Wang H, Castro B, et al. STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nat Commun. 2023;14(1):1610.","journal-title":"Nat Commun"},{"key":"2232_CR114","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.nano.2019.02.021","volume":"18","author":"HK Sanoff","year":"2019","unstructured":"Sanoff HK, Moon DH, Moore DT, Boles J, Bui C, Blackstock W, et al. Phase I\/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Nanomedicine. 2019;18:189\u201395.","journal-title":"Nanomedicine"},{"issue":"6","key":"2232_CR115","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2217\/nnm-2022-0186","volume":"18","author":"CW Huang","year":"2023","unstructured":"Huang CW, Hu HM, Hsu WH, Chen CY, Huang MY, Chen CP, et al. A phase Ib\/II trial of PEP503 (NBTXR3, radioenhancer) with radiotherapy and chemotherapy in patients with rectal cancer. Nanomedicine (Lond). 2023;18(6):511\u201324.","journal-title":"Nanomedicine (Lond)"},{"issue":"16","key":"2232_CR116","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1200\/JCO.2022.40.16_suppl.3603","volume":"40","author":"CW Huang","year":"2022","unstructured":"Huang CW, Wang JY, Chen CP, Wei PL, Hu HM, Hsu WH, et al. Phase 1b\/ 2 study of a radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemo-radiation in locally advanced or unresectable rectal cancer. J Clin Oncol. 2022;40(16):3603.","journal-title":"J Clin Oncol."},{"issue":"18","key":"2232_CR117","doi-asserted-by":"publisher","first-page":"18548","DOI":"10.1021\/acsnano.3c06774","volume":"17","author":"H Liao","year":"2023","unstructured":"Liao H, Yang S, Liang Z, Xiao L, Xie S, Lin P, et al. A Cancer Cell Selective Replication Stress Nano Amplifier Promotes Replication Fork Catastrophe to Overcome Radioresistance. ACS Nano. 2023;17(18):18548\u201361.","journal-title":"ACS Nano"},{"issue":"43","key":"2232_CR118","doi-asserted-by":"publisher","first-page":"e2404741","DOI":"10.1002\/smll.202404741","volume":"20","author":"R Li","year":"2024","unstructured":"Li R, Fu D, Yuan X, Niu G, Fan Y, Shi J, et al. Oral Heterojunction Coupling Interventional Optical Fiber Mediates Synergistic Therapy for Orthotopic Rectal Cancer. Small. 2024;20(43):e2404741.","journal-title":"Small"},{"issue":"18","key":"2232_CR119","doi-asserted-by":"publisher","first-page":"e2400845","DOI":"10.1002\/advs.202400845","volume":"11","author":"J Li","year":"2024","unstructured":"Li J, Wang Y, Shen W, Zhang Z, Su Z, Guo X, et al. Mitochondria-Modulating Liposomes Reverse Radio-Resistance for Colorectal Cancer. Adv Sci (Weinh). 2024;11(18):e2400845.","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"2232_CR120","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1021\/acscentsci.9b01121","volume":"6","author":"W Deng","year":"2020","unstructured":"Deng W, McKelvey KJ, Guller A, Fayzullin A, Campbell JM, Clement S, et al. Application of Mitochondrially Targeted Nanoconstructs to Neoadjuvant X-ray-Induced Photodynamic Therapy for Rectal Cancer. ACS Cent Sci. 2020;6(5):715\u201326.","journal-title":"ACS Cent Sci"},{"key":"2232_CR121","doi-asserted-by":"publisher","first-page":"101406","DOI":"10.1016\/j.nantod.2022.101406","volume":"43","author":"J Xu","year":"2022","unstructured":"Xu J, Liu Y, Liu S, Ou W, White A, Stewart S, et al. Metformin Bicarbonate-Mediated Efficient RNAi for Precise Targeting of TP53 Deficiency in Colon and Rectal Cancers. Nano Today. 2022;43:101406.","journal-title":"Nano Today."},{"key":"2232_CR122","doi-asserted-by":"publisher","first-page":"100317","DOI":"10.1016\/j.mtadv.2022.100317","volume":"16","author":"J Hao","year":"2022","unstructured":"Hao J, Yan QY, Li ZH, Liu XM, Peng J, Zhang T, et al. Multifunctional miR181a nanoparticles promote highly efficient radiotherapy for rectal cancer. Materials Today Advances. 2022;16:100317.","journal-title":"Materials Today Advances"},{"key":"2232_CR123","doi-asserted-by":"publisher","first-page":"120151","DOI":"10.1016\/j.biomaterials.2020.120151","volume":"255","author":"KJ Lee","year":"2020","unstructured":"Lee KJ, Ko EJ, Park YY, Park SS, Ju EJ, Park J, et al. A novel nanoparticle-based theranostic agent targeting LRP-1 enhances the efficacy of neoadjuvant radiotherapy in colorectal cancer. Biomaterials. 2020;255:120151.","journal-title":"Biomaterials"},{"key":"2232_CR124","doi-asserted-by":"publisher","first-page":"100809","DOI":"10.1016\/j.mtbio.2023.100809","volume":"23","author":"L Wang","year":"2023","unstructured":"Wang L, Zhang T, Zheng Y, Li Y, Tang X, Chen Q, et al. Combination of irinotecan silicasome nanoparticles with radiation therapy sensitizes immunotherapy by modulating the activation of the cGAS\/STING pathway for colorectal cancer. Mater Today Bio. 2023;23:100809.","journal-title":"Mater Today Bio"},{"issue":"1","key":"2232_CR125","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/10717544.2016.1272651","volume":"24","author":"FU Din","year":"2017","unstructured":"Din FU, Choi JY, Kim DW, Mustapha O, Kim DS, Thapa RK, et al. Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration. Drug Deliv. 2017;24(1):502\u201310.","journal-title":"Drug Deliv"},{"issue":"5","key":"2232_CR126","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1021\/bc0340924","volume":"14","author":"J Cheng","year":"2003","unstructured":"Cheng J, Khin KT, Jensen GS, Liu A, Davis ME. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem. 2003;14(5):1007\u201317.","journal-title":"Bioconjug Chem"},{"key":"2232_CR127","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","volume":"3","author":"B Muz","year":"2015","unstructured":"Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015;3:83\u201392.","journal-title":"Hypoxia (Auckl)"},{"issue":"1","key":"2232_CR128","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2232_CR129","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021;21(9):548\u201369.","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"2232_CR130","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1016\/j.cell.2022.07.025","volume":"185","author":"H Kalkavan","year":"2022","unstructured":"Kalkavan H, Chen MJ, Crawford JC, Quarato G, Fitzgerald P, Tait SWG, et al. Sublethal cytochrome c release generates drug-tolerant persister cells. Cell. 2022;185(18):3356\u201374 e22.","journal-title":"Cell."},{"issue":"7549","key":"2232_CR131","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nature14418","volume":"520","author":"Y Liu","year":"2015","unstructured":"Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 2015;520(7549):697\u2013701.","journal-title":"Nature"},{"issue":"10","key":"2232_CR132","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","volume":"35","author":"T Conroy","year":"2024","unstructured":"Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35(10):873\u201381.","journal-title":"Ann Oncol"},{"issue":"36","key":"2232_CR133","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1200\/JCO.20.01932","volume":"38","author":"J Zhu","year":"2020","unstructured":"Zhu J, Liu A, Sun X, Liu L, Zhu Y, Zhang T, et al. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer. J Clin Oncol. 2020;38(36):4231\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2232_CR134","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330\u20138.","journal-title":"Nat Rev Cancer"},{"key":"2232_CR135","doi-asserted-by":"publisher","first-page":"107447","DOI":"10.1016\/j.pharmthera.2019.107447","volume":"206","author":"S Vodenkova","year":"2020","unstructured":"Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther. 2020;206:107447.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"2232_CR136","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13346-020-00740-5","volume":"10","author":"JM Metselaar","year":"2020","unstructured":"Metselaar JM, Lammers T. Challenges in nanomedicine clinical translation. Drug Deliv Transl Res. 2020;10(3):721\u20135.","journal-title":"Drug Deliv Transl Res"},{"issue":"12","key":"2232_CR137","doi-asserted-by":"publisher","first-page":"100353","DOI":"10.1016\/j.crmeth.2022.100353","volume":"2","author":"JK Kim","year":"2022","unstructured":"Kim JK, Wu C, Del Latto M, Gao Y, Choi SH, Kierstead M, et al. An immunocompetent rectal cancer model to study radiation therapy. Cell Rep Methods. 2022;2(12):100353.","journal-title":"Cell Rep Methods"},{"issue":"10","key":"2232_CR138","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41591-019-0584-2","volume":"25","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Wu C, O\u2019Rourke KP, Szeglin BC, Zheng Y, Sauve CG, et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat Med. 2019;25(10):1607\u201314.","journal-title":"Nat Med"},{"issue":"1","key":"2232_CR139","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","volume":"26","author":"Y Yao","year":"2020","unstructured":"Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L, et al. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Cell Stem Cell. 2020;26(1):17\u201326 e6.","journal-title":"Cell Stem Cell."},{"issue":"5","key":"2232_CR140","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/jrr\/rraa041","volume":"61","author":"K Yasui","year":"2020","unstructured":"Yasui K, Kondou R, Iizuka A, Miyata H, Tanaka E, Ashizawa T, et al. Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients. J Radiat Res. 2020;61(5):766\u201375.","journal-title":"J Radiat Res"},{"issue":"3","key":"2232_CR141","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.adro.2017.04.001","volume":"2","author":"JR Gunther","year":"2017","unstructured":"Gunther JR, Chadha AS, Shin US, Park IJ, Kattepogu KV, Grant JD, et al. Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol. 2017;2(3):455\u201364.","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"2232_CR142","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2468-1253(22)00392-2","volume":"8","author":"JP Gerard","year":"2023","unstructured":"Gerard JP, Barbet N, Schiappa R, Magne N, Martel I, Mineur L, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(4):356\u201367.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02232-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02232-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02232-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T12:19:06Z","timestamp":1738239546000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02232-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":142,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2232"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02232-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}